When I was on an active hormone blockade (ADT2) I suffered extensively from many of the usually reported morbidity issues (negative side effects). One of the side effects I dealt with was significant cognitive impairment. I live in New York City, was born in the city and have spent most of my life in the [...]
Not a very big surprise but androgen-deprivation therapy (ADT) substantially increases the risk for cardiovascular and bone-related problems, as well as for diabetes, according to a review of the medical literature published online April 27 in the journal Cancer. At the University of Texas Health Science Center in Houston, Lockwood G. Taylor wrote a review [...]
A phase II trial was just completed at the University of Western Australia to investigate changes in bone mineral density (BMD) and osteoporosis in men on intermittent androgen-suppression therapy (IAST) over a period of three years. This trial, conducted at the Faculty of Medicine, University of Western Australia, Crawley, Department of Radiation Oncology, Sir Charles [...]
A new paper published in the Journal of Applied Psychology and co-authored by researchers from the University of Toronto’s Rotman School of Management and the University of British Columbia's Sauder School of Management concluded that sexual behavior at work creates a problem in the work place, especially morale. The study looks at sexual behavior in [...]
Presented at EAU on March 23, 2009 The drug Denosumab has shown itself both easy to tolerate by patients as well highly able to increases bone mineral density (BMD) when compared with placebo in men with nonmetastatic prostate cancer receiving androgen deprivation therapy (ADT). The results of this multi-centre, randomized, double-blind, placebo-controlled, phase 3 study [...]